EUVIMEDEUVIMED entdecken
Crossref

The incidence of brain metastases in breast cancer according to molecular subtype and stage: a 10-year single institution analysis

Christopher Poletes, Bardia Amanirad, Anna T Santiago, Michael Yan, Tatiana Conrad, Katarzyna J Jerzak, David B Shultz

Journal of Neuro-Oncology · 2024

DOI: 10.1007/s11060-024-04707-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2024. Verfasst von Christopher Poletes und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada. chris.poletes@gmail.com. Hauptthemen laut MEDLINE: Brain Neoplasms, Breast Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Breast cancer (BC) is the second most common etiology of brain metastases (BrM). We aimed to examine the incidence of BrM among all BC patients presenting to a large tertiary cancer centre over one decade. METHODS: We included all BC patients presenting consecutively between 2009 and 2019 and cross referenced that cohort to a radiotherapy database, identifying patients treated for BrM at any time following their initial presentation. Cumulative incidences (CI) of BrM diagnoses were calculated using death as a competing risk and compared using the Fine-Gray method. Overall survival was estimated using the Kaplan Meier method. RESULTS: We identified 12,995 unique patients. The CI of BrM in patients who initially presented with Stage 0-4 disease was 2.1%, 3.7%, 9.4%, 10.6%, and 28.7%, respectively at 10 years. For 8,951 patients with available molecular subtype data, 6,470 (72%), 961 (11%), 1,023 (11%), and 497 (6%) had hormone-receptor (HR)-positive/ERBB2-, HR-negative/ERBB2-, HR-positive/ERBB2 + , and HR-negative/ERBB2 + disease, respectively; the CI of BrM in each was 7.6%, 25.3%, 24.1%, and 26.6%, at 10 years following BC diagnosis, respectively. Median overall survival (OS) following BC diagnosis and BrM diagnosis was 28 years 95% CI [25, 32] and 10 months 95% CI [9, 12], respectively. CONCLUSIONS: From a large, registry-based study, we observed that patients with ERBB2 + and triple negative BC have the highest incidence of BrM. Our data supports prospective surveillance brain MRI studies. Given advancements in BrM treatment, clinicians should have a low threshold for brain imaging in BC patients with high risk subtypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsBreast NeoplasmsHumansFemaleMiddle AgedIncidenceAdultAgedNeoplasm StagingFollow-Up StudiesErb-b2 Receptor Tyrosine KinasesRetrospective StudiesAged, 80 and overSurvival RatePrognosis

Stichwörter der Autor:innen

Brain metastasesBreast cancerERBB2 +HER2 +Molecular subtypeTrastuzumabTriple negative

Substanzen

Erb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada. chris.poletes@gmail.com.
  • Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. chris.poletes@gmail.com.
  • Royal College of Surgeons in Ireland, Dublin, Ireland. chris.poletes@gmail.com.
  • Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
  • Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Department of Biostatistics, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Canada.

Zitieren

APA

Poletes, C., Amanirad, B., Santiago, A. T., Yan, M., Conrad, T., Jerzak, K. J., & Shultz, D. B. (2024). The incidence of brain metastases in breast cancer according to molecular subtype and stage: a 10-year single institution analysis. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04707-1

Vancouver

Poletes C, Amanirad B, Santiago AT, Yan M, Conrad T, Jerzak KJ, et al. The incidence of brain metastases in breast cancer according to molecular subtype and stage: a 10-year single institution analysis. Journal of Neuro-Oncology. 2024. doi:10.1007/s11060-024-04707-1

BibTeX
@article{Poletes2024,
  author = {Poletes, Christopher and Amanirad, Bardia and Santiago, Anna T and Yan, Michael and Conrad, Tatiana and Jerzak, Katarzyna J and Shultz, David B},
  title = {The incidence of brain metastases in breast cancer according to molecular subtype and stage: a 10-year single institution analysis},
  journal = {Journal of Neuro-Oncology},
  year = {2024},
  doi = {10.1007/s11060-024-04707-1}
}
Kostenlos starten →